An Open-Label Study to Investigate the Effect of Renal Impairment on the Pharmacokinectics of Tenofovir Exalidex

Trial Profile

An Open-Label Study to Investigate the Effect of Renal Impairment on the Pharmacokinectics of Tenofovir Exalidex

Completed
Phase of Trial: Phase I

Latest Information Update: 08 Mar 2018

At a glance

  • Drugs Tenofovir exalidex (Primary)
  • Indications Hepatitis B
  • Focus Pharmacokinetics
  • Sponsors ContraVir Pharmaceuticals
  • Most Recent Events

    • 06 Feb 2018 According to a ContraVir Pharmaceuticals media release, company plans to present additional results at future scientific meetings.
    • 06 Feb 2018 Status changed from recruiting to completed, according to a ContraVir Pharmaceuticals media release.
    • 19 Oct 2017 According to a ContraVir Pharmaceuticals media release, first patient has been dosed.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top